Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study - ONCOSTAT Access content directly
Journal Articles Cancer Medicine Year : 2022

Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study

Sarah Watson
Stanislas Ropert
  • Function : Author
Matthieu Faron
Olivier Mir

Abstract

Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single‐agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single‐agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI‐CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single‐agent gemcitabine has clinically meaningful activity in advanced, heavily pre‐treated angiosarcoma.
Fichier principal
Vignette du fichier
Cancer Medicine - 2022 - Watson - Single‐agent gemcitabine in patients with advanced pre‐treated angiosarcoma A.pdf (436.96 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
licence

Dates and versions

hal-04520147 , version 1 (05-06-2024)

Licence

Identifiers

Cite

Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, et al.. Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study. Cancer Medicine, 2022, 12 (3), pp.3160-3166. ⟨10.1002/cam4.5147⟩. ⟨hal-04520147⟩
51 View
4 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More